A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)

被引：0
作者：
Matthew Gumbleton
Stephanie Allan
Hannah Conway
Kenneth Boucher
James Marvin
Josiah Hawks
William Burnett
Matthew Van Brocklin
Jonathan Whisenant
Glynn Gilcrease
Sumati Gupta
机构：
[1] University of Utah,Huntsman Cancer Institute
[2] University of Utah School of Medicine,Division of Oncology, Department of Internal Medicine
[3] University of Utah School of Medicine,Division of Epidemiology and Huntsman Cancer Institute, Department of Internal Medicine
[4] University of Utah,Flow Cytometry Core Facility, Health Science Center
[5] University of Utah School of Medicine,Department of Oncological Sciences
[6] University of Utah School of Medicine,Division of Oncology, Department of Surgery
[7] Department of Veterans Affairs Medical Center,undefined
来源：
BMC Research Notes | / 16卷
关键词：
APPEASE; Apatinib; Rivoceranib; Pembrolizumab; Immunotherapy; VEGF inhibition;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 132 条
[21]  
Bang YJ(2020)Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial J Immunother Cancer. undefined undefined-undefined
[22]  
Di Bartolomeo M(2019)Anti - PD - 1 antibody SHR - 1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open - label, dose escalation and expansion study Clin Cancer Res undefined undefined-undefined
[23]  
Mandala M(2020)Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study Onco Targets Ther undefined undefined-undefined
[24]  
Ryu MH(undefined)undefined undefined undefined undefined-undefined
[25]  
Powles T(undefined)undefined undefined undefined undefined-undefined
[26]  
Duran I(undefined)undefined undefined undefined undefined-undefined
[27]  
van der Heijden MS(undefined)undefined undefined undefined undefined-undefined
[28]  
Loriot Y(undefined)undefined undefined undefined undefined-undefined
[29]  
Vogelzang NJ(undefined)undefined undefined undefined undefined-undefined
[30]  
De Giorgi U(undefined)undefined undefined undefined undefined-undefined
12345678910